Ohsu Knight Cancer Institute
- Country
- ๐บ๐ธUnited States
- Ownership
- Subsidiary
- Employees
- -
- Market Cap
- -
Methotrexate, Cyclophosphamide, and Etoposide Phosphate Given With Osmotic Blood-Brain Barrier Disruption Plus Dexamethasone and Cytarabine in Treating Patients With Primary CNS Lymphoma
- Conditions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 22
- Registration Number
- NCT00074178
- Locations
- ๐บ๐ธ
Oregon Health & Science University Cancer Institute, Portland, Oregon, United States
Methotrexate, Procarbazine, Lomustine, Dexamethasone, and Cytarabine in Treating Patients With Primary CNS Lymphoma
- Conditions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2017-04-21
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 1
- Registration Number
- NCT00074191
- Locations
- ๐บ๐ธ
Oregon Health & Science University Cancer Institute, Portland, Oregon, United States
Raloxifene With or Without Exercise Compared With Exercise Alone in Women Who Have Been Previously Treated for Breast Cancer
- Conditions
- First Posted Date
- 2003-08-06
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 80
- Registration Number
- NCT00031811
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2003-01-28
- Last Posted Date
- 2012-05-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 16
- Registration Number
- NCT00053248
- Locations
- ๐บ๐ธ
UCLA Department of Medicine, Division of Hematology/Oncology, Los Angeles, California, United States
๐บ๐ธOHSU Knight Cancer Institute, Portland, Oregon, United States
๐บ๐ธH. Lee Moffitt Cancer Center, Tampa, Florida, United States
Imatinib Mesylate Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-01-07
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 24
- Registration Number
- NCT00022490
- Locations
- ๐บ๐ธ
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
๐บ๐ธOHSU Knight Cancer Institute, Portland, Oregon, United States
Imatinib Mesylate and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2012-08-20
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT00015847
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
๐บ๐ธRobert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois, United States
Combination Chemotherapy Followed by Surgery in Treating Patients With Localized Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 57
- Registration Number
- NCT00017563
- Locations
- ๐บ๐ธ
OHSU Knight Cancer Institute, Portland, Oregon, United States
๐บ๐ธPortland VA Medical Center, Portland, Oregon, United States